Factor VIII - Novo NordiskAlternative Names: Factor VIII - NovoNordisk; Nordiate
Latest Information Update: 14 Jul 1998
At a glance
- Originator Novo Nordisk
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Marketed Haemophilia